Antengene announces commercial availability of xpovio® (selinexor), for the treatment of relapsed/refractory multiple myeloma, prescribed for the first time across mainland china

-distribution channels in place to streamline/facilitate patient access. -xpovio® will be available in 600 hospitals and 105 dtps ( across china including beijing, shanghai, guangdong, jiangsu, zhejiang, henan, and shandong ).

KPTI Ratings Summary

KPTI Quant Ranking